Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Oct 31, 2025 | (Q2)Jul 31, 2025 | (Q1)Apr 30, 2025 | (FY)Jan 31, 2025 | (Q4)Jan 31, 2025 | (Q3)Oct 31, 2024 | (Q2)Jul 31, 2024 | (Q1)Apr 30, 2024 | (FY)Jan 31, 2024 | (Q4)Jan 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 61.42%-93.55K | 24.69%-312.79K | -1,642.86%-218.65K | -14.06%-709.87K | 61.40%-66.18K | -450.74%-242.52K | -7.59%-415.35K | 168.11%14.17K | 30.90%-622.36K | -89.60%-171.46K |
| Net income from continuing operations | 44.56%-88.54K | -31.06%-216.54K | -54.69%-310.88K | 36.63%-982.78K | 56.73%-456.88K | -54.54%-159.7K | 31.09%-165.23K | -32.28%-200.97K | 22.98%-1.55M | -29,919.08%-1.06M |
| Operating gains losses | 104.19%1.94K | -83.22%2.4K | 126.49%909 | 99.81%-108 | 151.85%35.35K | -561.24%-46.3K | 178,325.00%14.27K | -38,022.22%-3.43K | 39.21%-58.14K | 27.07%-68.18K |
| Depreciation and amortization | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
| Asset impairment expenditure | ---- | ---- | ---- | -87.64%109.63K | ---- | ---- | ---- | ---- | --886.71K | ---- |
| Remuneration paid in stock | --10.52K | --16.21K | --202.03K | --0 | --0 | --0 | --0 | --0 | -98.41%14.8K | --0 |
| Other non cashItems | -93.34%2.71K | 42.28%-25.5K | 7,615.04%41.04K | -24.99%3.03K | -1.98%5.99K | 2,043.31%40.69K | -765.71%-44.19K | -89.62%532 | 367.82%4.04K | 112.90%6.11K |
| Change In working capital | 73.86%-20.18K | 59.43%-89.34K | -169.60%-151.76K | 97.80%160.36K | 301.76%239.74K | -250.34%-77.21K | -41.19%-220.21K | 73.04%218.04K | -67.84%81.07K | 73.44%59.67K |
| -Change in receivables | 268.21%21.83K | -308.46%-11.64K | 50.28%-4.06K | -244.52%-26.93K | -185.96%-2.93K | -213.51%-12.98K | 49.32%-2.85K | -186.80%-8.17K | 187.64%18.63K | 137.90%3.41K |
| -Change in prepaid assets | -74.76%8.13K | 65.04%-28.95K | -84.48%3.4K | 363.36%40.03K | 211.14%68.71K | -8.05%32.22K | 17.80%-82.82K | -22.93%21.92K | -107.24%-15.2K | -22.33%22.08K |
| -Change in payables and accrued expense | 48.01%-50.15K | 63.76%-48.75K | -173.97%-151.1K | 89.69%147.26K | 409.00%173.96K | -2,072.39%-96.45K | -171.32%-134.54K | 131.74%204.28K | 22.57%77.63K | 128.24%34.18K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 61.42%-93.55K | 24.69%-312.79K | -1,642.86%-218.65K | -14.06%-709.87K | 61.40%-66.18K | -450.74%-242.52K | -7.59%-415.35K | 168.11%14.17K | 30.90%-622.36K | -89.60%-171.46K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -74.49%-228.18K | -880.49%-398.3K | -100.87%-179.3K | 54.06%-382.82K | -67.29%-122.16K | 63.53%-130.77K | 80.39%-40.62K | 54.09%-89.26K | 35.37%-833.24K | 86.82%-73.02K |
| Capital expenditure reported | ---- | ---- | ---- | 94.75%-46.44K | ---- | ---- | ---- | ---- | ---884.07K | ---- |
| Net PPE purchase and sale | -18,347.43%-31.93K | -430.87%-80.93K | ---7.49K | -56.35%22.18K | -104.83%-2.45K | --175 | --24.46K | --0 | 243.74%50.82K | 246.18%50.82K |
| Net other investing changes | ---- | ---- | -92.48%-171.81K | 56.97%-358.56K | -0.34%-73.27K | ---- | ---- | 54.09%-89.26K | 33.55%-833.24K | 85.93%-73.02K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -74.49%-228.18K | -880.49%-398.3K | -100.87%-179.3K | 54.06%-382.82K | -67.29%-122.16K | 63.53%-130.77K | 80.39%-40.62K | 54.09%-89.26K | 35.37%-833.24K | 86.82%-73.02K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 8.20%296.89K | 4.55%711.91K | 1,406.67%488.16K | -20.12%1.11M | -40.98%122.07K | -11.03%274.39K | -5.77%680.95K | -78.61%32.4K | 125.33%1.39M | -57.11%206.84K |
| Net issuance payments of debt | ---- | ---- | ---- | --13.8K | --0 | ---- | ---- | ---- | --0 | --0 |
| Net common stock issuance | 5.10%303.89K | 21.13%814.91K | --442K | -21.69%1.12M | -36.47%154K | -75.55%289.14K | --672.75K | --0 | 123.19%1.42M | -49.74%242.42K |
| Net other financing activities | 75.48%-7K | -1,356.10%-103K | 42.47%46.16K | 44.12%-19.88K | ---31.93K | ---28.55K | -98.87%8.2K | -78.61%32.4K | ---35.58K | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 8.20%296.89K | 4.55%711.91K | 1,406.67%488.16K | -20.12%1.11M | -40.98%122.07K | -11.03%274.39K | -5.77%680.95K | -78.61%32.4K | 125.33%1.39M | -57.11%206.84K |
| Net cash flow | ||||||||||
| Beginning cash position | -64.19%53.54K | 6,468.66%35.21K | -97.23%563 | -71.09%20.32K | -44.74%9.27K | 30.60%149.5K | -95.35%536 | -71.09%20.32K | -95.75%70.3K | -76.98%16.78K |
| Current changes in cash | 74.88%-24.84K | -99.63%824 | 311.31%90.21K | 125.86%17.12K | -76.08%-66.27K | -4.95%-98.91K | 73.84%224.98K | 33.03%-42.69K | 95.79%-66.2K | 76.77%-37.64K |
| Effect of exchange rate changes | 131.78%13.13K | 123.03%17.51K | -342.58%-55.56K | -327.33%-36.88K | 39.79%57.56K | -1,095.08%-41.33K | -187.24%-76.01K | 361.12%22.9K | 281.79%16.22K | -74.17%41.18K |
| End cash Position | 351.14%41.83K | -64.19%53.54K | 6,468.66%35.21K | -97.23%563 | -97.23%563 | -44.74%9.27K | 30.60%149.5K | -95.35%536 | -71.09%20.32K | -71.09%20.32K |
| Free cash from | 512.48%363.7K | -54.98%-882.9K | -1,695.68%-226.14K | 49.79%-756.31K | 89.33%-112.61K | -124.66%-88.17K | 27.67%-569.69K | 168.11%14.17K | -60.94%-1.51M | -743.09%-1.06M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.